Biovie Inc (BIVI) @ NASDAQ
Printed Sunday, 5 July '26 10:57 MST
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.
Biotechnology Common Stock β +0.649
| Date | Name (*Public) | Description | Symbol | Type | Size | Action |
|---|
| Date | Value | Error | Logarithmic | Error | Model (*Public) |
|---|
-$0.23 (10.55%) on Thursday, 2 July 2026, Marketcap $14.71 M
| Date | Value | Δ | Open | Close | Low | High | Adjusted | Volume | Δ |
|---|
| Name | Version (*Public) | Indicator % | Auto | Description | Symbol | Company Name | Forecasts | Buy / Sell | Action |
|---|
| Opened (Closed) | Expires | Symbol | Company Name | Name (*Public) | Size | Contract Symbol | Open P/L | Close P/L | Total P/L | ROI | DTE | DIT | Delta | Action |
|---|
| Details | Best Trend by Hindsight | Forecast | Profit or Loss | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date (*Public) | Symbol | Strategy | Data | Origin | Slope | Sigma | Cor % | Moves | Sigma | Moves | Gain % | Periods | Action |
| Date | Name (*Public) | Description | Price | Quantity | Total | Cost | Type | Symbol | Action |
|---|
| Date | RSI | Stochastic %D | Stochastic %K | MACD | MACD Divergence | MACD Signal | DMI | CCI | Volatility | Bollinger Upper | Bollinger Mid | Bollinger Lower |
|---|
| Date | Name | Description | Type | Symbol | Company Name | Location |
|---|
| Date UTC | Location | Action | Description | Object | Severity | User | Action |
|---|